Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Contemp Clin Trials. 2020 Apr 15;92:106001. doi: 10.1016/j.cct.2020.106001

Table 1.

Inclusion and exclusion criteria.

Inclusion criteria Exclusion criteria
 ■ Females with pathologically confirmed breast cancer  ■ Stage IV breast cancer
 ■ Stage I–III  ■ Patients with end-stage disease, severe dementia and/or life expectancy of less than one year
 ■ Age: 65 years and older  ■ Inability to understand English as study instruments have not been validated in other languages
 ■ Have completed primary surgery (Lumpectomy or mastectomy)  ■ Inability to provide informed consent
 ■ Are within five years of treatment completion (primary surgery, chemotherapy or radiation therapy), whichever was received last  ■ High-riska patients for Cardiovascular Disease per the ASCM/AHA pre-exercise screening questionnaire who do not receive medical clearance from a physician
 ■ Adjuvant hormonal therapy and targeted therapy are allowed  ■ Other medical or psychological conditions that would make participation unsafe or inhibit our ability to test our primary hypothesis, e.g. Parkinson’s disease, severe arthritis
 ■ Race: African-Americans and Non-Hispanic Whites
a

High risk denotes women with known or signs/symptoms of cardiac, pulmonary and/or metabolic disease such as diabetes